Peroxisome proliferator-activated receptor-α activation decreases mean arterial pressure, plasma interleukin-6, and COX-2 while increasing renal CYP4A expression in an acute model of DOCA-salt hypertension

PPAR Research

Volumn , Issue , 2011, Pages

  Lee, Dexter L ^a   Wilson, Justin L ^a   Duan, Rong ^a   Hudson, Tamaro ^b   El Marakby, Ahmed ^c  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 2C23; CYTOCHROME P450 4A; DEOXYCORTICOSTERONE ACETATE; EPOXIDE HYDROLASE; FENOFIBRATE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; KIDNEY HOMOGENATE; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TELEMETRY; UNINEPHRECTOMY;

EID: 84862917714     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2011/502631     Document Type: Article

References (31)

1. Obih P., Oyekan A., Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPAR null mice Blood Pressure 2008 17 1 55 63 (Pubitemid 351890493)
2. Roman R. J., Ma Y. H., Frohlich B., Markham B., Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats Hypertension 1993 21 6 985 988 (Pubitemid 23166953)
3. Vera T., Taylor M., Bohman Q., Flasch A., Roman R. J., Stec D. E., Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice Hypertension 2005 45 4 730 735 (Pubitemid 40418373)
4. Williams J. M., Zhao X., Wang M. H., Imig J. D., Pollock D. M., Peroxisome proliferator-activated receptor- activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade Hypertension 2005 46 2 366 371 (Pubitemid 41099171)
5. Wilson T. W., Alonso-Galicia M., Roman R. J., Effects of lipid-lowering agents in the Dahl salt-sensitive rat Hypertension 1998 31 1 225 231
6. Zhou Y., Luo P., Chang H. H., Huang H., Yang T., Dong Z., Wang C. Y., Wang M. H., Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension Kidney International 2008 74 8 1040 1048
7. Guan Y., Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome Journal of the American Society of Nephrology 2004 15 11 2801 2815 (Pubitemid 41103389)
8. Newaz M., Blanton A., Fidelis P., Oyekan A., NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) -mediated cardiovascular effects Mutation ResearchFundamental and Molecular Mechanisms of Mutagenesis 2005 579 1-2 163 171 (Pubitemid 41540140)
9. Newaz M. A., Ranganna K., Oyekan A. O., Relationship between PPAR activation and NO on proximal tubular Na + transport in the rat BMC Pharmacology 2004 4 1
10. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131 (Pubitemid 29289077)
11. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., Delerive P., Fadel A., Chinetti G., Fruchart J. C., Najib J., Maclouf J., Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators Nature 1998 393 6687 790 793 (Pubitemid 28299490)
12. Chae C. U., Lee R. T., Rifai N., Ridker P. M., Blood pressure and inflammation in apparently healthy men Hypertension 2001 38 3 399 403 (Pubitemid 34225673)
13. Ferrario C. M., Strawn W. B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease American Journal of Cardiology 2006 98 1 121 128 (Pubitemid 43902687)
14. Seifi B., Kadkhodaee M., Xu J., Soleimani M., Pro-inflammatory cytokines of rat vasculature in DOCA-salt treatment Molecular Biology Reports 2010 37 4 2111 2115
15. Babaev V. R., Ishiguro H., Ding L., Yancey P. G., Dove D. E., Kovacs W. J., Semenkovich C. F., Fazio S., Linton M. F., Macrophage expression of peroxisome proliferator-activated receptor- reduces atherosclerosis in low-density lipoprotein receptor-deficient mice Circulation 2007 116 12 1404 1412 (Pubitemid 47417567)
16. Krysiak R., Gdula-Dymek A., Okopien B., Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia American Journal of Cardiology 2011 107 7 1010 1018
17. Coles B., Fielding C. A., Rose-John S., Scheller J., Jones S. A., O'Donnell V. B., Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo American Journal of Pathology 2007 171 1 315 325 (Pubitemid 47339248)
18. Lee D. L., Sturgis L. C., Labazi H., Osborne J. B., Fleming C., Pollock J. S., Manhiani M., Imig J. D., Brands M. W., Angiotensin II hypertension is attenuated in interleukin-6 knockout mice American Journal of PhysiologyHeart and Circulatory Physiology 2006 290 3 H935 H940
19. Wang Y., Wang D. H., Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension American Journal of PhysiologyRenal Physiology 2009 297 6 F1550 F1559
20. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama-Tomobe Y., Yamaguchi I., Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway Journal of the American College of Cardiology 2004 43 8 1481 1488 (Pubitemid 38496358)
21. Guzik T. J., Hoch N. E., Brown K. A., McCann L. A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D. G., Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction Journal of Experimental Medicine 2007 204 10 2449 2460 (Pubitemid 47529329)
22. Sturgis L. C., Cannon J. G., Schreihofer D. A., Brands M. W., The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6 American Journal of PhysiologyRegulatory Integrative and Comparative Physiology 2009 297 6 R1742 R1748
23. Gross V., Schneider W., Schunck W. H., Mervaala E., Luft F. C., Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice Journal of the American Society of Nephrology 1999 10 7 1430 1439 (Pubitemid 29297517)
24. Cheng H. F., Wang C. J., Moeckel G. W., Zhang M. Z., McKanna J. A., Harris R. C., Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension Kidney International 2002 62 3 929 939 (Pubitemid 35316722)
25. Adeagbo A. S. O., Zhang X., Patel D., Joshua I. G., Wang Y., Sun X., Igbo I. N., Oriowo M. A., Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension Journal of Hypertension 2005 23 5 1025 1036 (Pubitemid 40637922)
26. Bae E. H., Kim I. J., Ma S. K., Kim S. W., Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats Hypertension Research 2010 33 3 255 262
27. Honeck H., Gross V., Erdmann B., Krgel E., Neunaber R., Milia A. F., Schneider W., Luft F. C., Schunck W. H., Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice Hypertension 2000 36 4 610 616
28. Imig J. D., Zhao X., Capdevila J. H., Morisseau C., Hammock B. D., Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension Hypertension 2002 39 2 690 694 (Pubitemid 34165207)
29. Manhiani M., Quigley J. E., Knight S. F., Tasoobshirazi S., Moore T., Brands M. W., Hammock B. D., Imig J. D., Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension American Journal of PhysiologyRenal Physiology 2009 297 3 F740 F748
30. Imig J. D., Elmarakby A. A., Nithipatikom K., Development of epoxyeicosatrienoic acids analogs with in vivo anti-hypertensive actions Frontiers in Physiology 2010 1 1 8
31. Rszer T., Ricote M., PPARs in the renal regulation of systemic blood pressure PPAR Research 2010 2010 11